ライフサイエンスコーパス: erythromycin

1 o penicillin and fluoroquinolones but not to erythromycin.

2 nd in the soil bacterium that biosynthesizes erythromycin.

3 omplexes in the OM decreases permeability to erythromycin.

4 e synergistic effects of our inhibitors with erythromycin.

5 deT1 renders E. coli cells more resistant to erythromycin.

6 sizes the macrocyclic core of the antibiotic erythromycin.

7 hway for the widely used antibacterial agent erythromycin.

8 codon and is de-repressed by the presence of erythromycin.

9 a molecule that kills other bacteria, i.e., erythromycin.

10 e of the broad spectrum macrolide antibiotic erythromycin.

11 ed resistance when exposed to 0.25 microg/ml erythromycin.

12 tentiation of the activity of novobiocin and erythromycin.

13 ons causing variable levels of resistance to erythromycin.

14 group with the exception of tetracycline and erythromycin.

15 sistance pattern of the VGS to penicillin or erythromycin.

16 to rifampin and the translational inhibitor erythromycin.

17 5 mug/L for ciprofloxacin to 1,250 mug/L for erythromycin.

18 eneration macrolide antibiotic prepared from erythromycin (1) and used clinically since 2004.

19 vasive isolates (36%) were nonsusceptible to erythromycin, 19 isolates (43%) were nonsusceptible to t

20 On consecutive days, erythromycin (200 mg in 20 mL 0.9% saline) or placebo (2

21 randomization, the subjects received either erythromycin 250 mg or neomycin 1 g orally QID until hos

22 for ciprofloxacin (4 mug/mL from 1 mug/mL), erythromycin (256 mug/mL from 4 mug/mL), and penicillin

23 aadA1 (for streptomycin; 33.50%), ereA (for erythromycin; 27.41%), aac-3-IV (for gentamicin; 25.38%)

24 A trend to slower transit was observed after erythromycin [300 (39-360) compared with 228 (33-360) mi

25 esistance to tetracycline (58.2%, 53/91) and erythromycin (38.5%, 35/91), whereas in S. aureus the re

26 Erythromycin (39.5%) and clindamycin (26.4%) resistance

27 239 patients received erythromycin, 410 patients received domperidone.

28 ythromycin or no co-amoxiclav, respectively (erythromycin: 53 [3.3%] of 1611 vs 27 [1.7%] of 1562, 1.

29 d with those born to mothers who received no erythromycin (594 [38.3%] of 1551 children vs 655 [40.4%

30 sizes the macrocyclic core of the antibiotic erythromycin 6-deoxyerythronolide B.

31 than did those whose mothers had received no erythromycin (658 [42.3%] of 1554 children vs 574 [38.3%

32 nd in 91% of isolates that were resistant to erythromycin (68/75).

33 st and BMD resulted in lower concordance for erythromycin (73.9%), clindamycin (65.5%), and trimethop

34 sceptible to all antimicrobial agents except erythromycin (79.1 and 76.0% susceptibilities in the 200

35 esistance to tetracycline (53.2% resistant), erythromycin (80.8% resistant or intermediate resistant)

36 ) for hVISA were as follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%;

37 eflected in AMR patterns, with a decrease in erythromycin (86.7% to 78.4%, P = .036) and clindamycin

38 tion was >96% for all the antibiotics except erythromycin (92.1%) and clindamycin (89.5%).

39 lentine leukocidin (96.3%), and resistant to erythromycin (94.1%) and, less commonly, levofloxacin (5

40 4.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addit

41 -dihydro-9-acetamido-N-desmethyl-N-isopropyl erythromycin A analogues and related derivatives was gen

42 The macrolide antibiotic erythromycin A and its semisynthetic analogues have been

43 vel antibiotic that not only is as potent as erythromycin A with respect to its ability to inhibit ba

44 cursor-directed biosynthesis of 15-propargyl erythromycin A, a novel antibiotic that not only is as p

45 ndustrial-scale production of the antibiotic erythromycin A, derivatives of which play a vital role i

46 Three polyketide natural products, namely erythromycin A, lasalocid A, and iso-lasalocid A, were s

47 g the acid-catalyzed degradation reaction of erythromycin A.

48 l drugs--norfloxacin, a fluoroquinolone, and erythromycin, a macrolide--proteins with single mutation

49 Erythromycin, a non-peptide motilin receptor agonist, in

50 At 0.5 microg/ml erythromycin, a total of eight strains (four Campylobact

51 general anesthesia for emergency procedures, erythromycin administration increased the proportion wit

52 Last, the effect of erythromycin administration on food intake was examined

53 ith bronchiectasis, with and without chronic erythromycin administration, and healthy control subject

54 clinical symptoms of constipation following erythromycin administration, but the effect on colon mot

55 lebseilla pneumoniae infections in mice than erythromycin alone or in combination with H-TriA1.

56 penicillin, streptomycin, tetracycline, and erythromycin, among others.

57 Saccharopolyspora erythraea makes erythromycin, an antibiotic commonly used in human medic

58 this murine study, topical application of 2% erythromycin and 3% tetracycline preparations that are a

59 eater frequency of gastric contractions with erythromycin and a reduced frequency of gastric contract

60 apparently increasing its affinity for both erythromycin and ATP.

61 inical isolates with increased resistance to erythromycin and azithromycin frequently harbour mutatio

62 our structures of the macrolide antibiotics erythromycin and azithromycin in complex with a bacteria

63 ecies were also resistant to clindamycin and erythromycin and carried the erm(A) (S. pseudoporcinus)

64 ion limits in environmental risk assessment, erythromycin and ciprofloxacin were estimated to inhibit

65 were acquired locally and were resistant to erythromycin and ciprofloxacin.

66 s collaborative study assessed two different erythromycin and clindamycin concentration combinations

67 a disk approximation test (D-zone test) with erythromycin and clindamycin disks and a single-well bro

68 disks and a single-well broth test combining erythromycin and clindamycin for detection of inducible

69 single-well microdilution test incorporating erythromycin and clindamycin in combination is a sensiti

70 ancomycin, but 32% and 15% were resistant to erythromycin and clindamycin, respectively.

71 ll antibiotic classes tested or resistant to erythromycin and clindamycin.

72 SA and SpeC, and resistance to tetracycline, erythromycin and clindamycin.

73 e antimicrobial and anticancer drugs such as erythromycin and doxorubicin.

74 The remaining two antibiotics (erythromycin and doxycycline) showed some intermediates

75 s chloroplast protein synthesis sensitive to erythromycin and exposure to cold.

76 ontrauma, the association between receipt of erythromycin and having a clear stomach (adjusted odds r

77 Macrolide antibiotics, such as erythromycin and josamycin, are natural polyketide produ

78 ide occurs in the presence of the antibiotic erythromycin and leads to induction of expression of the

79 BldD concurrently regulates the synthesis of erythromycin and morphological differentiation.

80 sensors that respond to acrylate, glucarate, erythromycin and naringenin.

81 Erythromycin and oleandomycin, when bound to OleD and Ol

82 mal proteins L4 and L22 confer resistance to erythromycin and other macrolide antibiotics in a variet

83 are responsible for the biosynthesis of the erythromycin and pikromycin 14-membered ring aglycones,

84 n) AUC in the colon during the fasting, post-erythromycin and postprandial phases of the study was 2.

85 ed organisms, including antibiotics, such as erythromycin and rifamycins.

86 gG expression alone allowed translocation of erythromycin and small periplasmic proteins across the o

87 . that confers resistance to the antibiotics erythromycin and tetracycline (Tc).

88 ddition to carrying resistance genes to both erythromycin and tetracycline, CTnDOT carries a gene tha

89 For erythromycin and tetracycline, differences in MICs betwe

90 nt antibiotics - isoniazid, chloramphenicol, erythromycin and tetracycline.

91 tal structure of the MphR(A) protein free of erythromycin and that of the MphR(A) protein with bound

92 The ORACLE II trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxicla

93 The ORACLE I trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxicla

94 creened, 117 were randomized (58 placebo, 59 erythromycin), and 107 (91.5%) completed the study.

95 High levels of tetracycline, multidrug, erythromycin, and aminoglycoside resistance genes were d

96 Resistance to tetracycline, erythromycin, and clindamycin was seen in 11% (n = 8), 5

97 NCTC1 was resistant to penicillin and erythromycin, and contained a complement of chromosomal

98 jority of isolates (92.4%) were resistant to erythromycin, and high clindamycin resistance rates were

99 sual sugar found on the macrolide antibiotic erythromycin, and it has been shown to play a critical r

100 y were observed for amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pneumoniae and f

101 , erythromycin, clindamycin, penicillin plus erythromycin, and multiple drugs (>/=3 antibiotics) was

102 and 23.5% were susceptible to ciprofloxacin, erythromycin, and penicillin, respectively.

103 0 through 2001, occurred with ciprofloxacin, erythromycin, and penicillin.

104 acceleration of gastric emptying induced by erythromycin, and retardation of gastric motility caused

105 We identified 12 erythromycin- and clindamycin-resistant emm 90 group A s

106 (89%) were clonally related, tetracycline-, erythromycin-, and clindamycin-resistant sequence type 4

107 d to sequence type (ST)459, a tetracycline-, erythromycin-, and clindamycin-resistant ST first identi

108 tions for injectable penicillin and for oral erythromycin are downgraded.

109 bservations have implications for the use of erythromycin as a gastrokinetic drug in the critically i

110 Our aim was to evaluate the efficacy of erythromycin as an HE treatment.

111 n and that of the MphR(A) protein with bound erythromycin at 2.00- and 1.76-A resolutions, respective

112 Erythromycin, avermectin and rapamycin are clinically us

113 High MICs for erythromycin, azithromycin, and clindamycin, and interme

114 We conclude that erythromycin B 2'-ethyl succinate is an attractive prosp

115 Macrolide antibiotics, exemplified by erythromycin, bind the 50S subunit with nM affinity and

116 Purified L22 Lys90Trp ribosomes show reduced erythromycin binding but have the same affinity for tylo

117 Erythromycin binds to OleD and the 23S RNA of its target

118 six different modules of the PKS involved in erythromycin biosynthesis (6-deoxyerythronolide B syntha

119 Unusually, the erythromycin biosynthetic (ery) cluster lacks a pathway-

120 EBS2, and DEBS3, which are housed within the erythromycin biosynthetic gene cluster.

121 robing and molecular dynamics simulations of erythromycin-bound ribosomes showed that the antibiotic

122 emic toxins on CYP3A4 activity using the 14C-erythromycin breath test and the traditional phenotypic

123 The erythromycin breath test was evaluated to determine hepa

124 s one such allele that confers resistance to erythromycin but not to tylosin and spiramycin.

125 A isolates were resistant to clindamycin and erythromycin, but CA-MRSA was more susceptible to sulfam

126 Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P

127 compared nonsusceptibility to penicillin and erythromycin by geography after standardizing difference

128 nated by organisms other than P. aeruginosa, erythromycin caused a significant change in microbiota c

129 Macrolide antibiotics, like erythromycin, clarithromycin, and azithromycin, possess

130 MICs of erythromycin, clarithromycin, azithromycin, rifampin, ge

131 In general, resistance rates to erythromycin, clindamycin, and levofloxacin were higher

132 Tetracycline, erythromycin, clindamycin, and metronidazole revealed po

133 of pneumococci nonsusceptible to penicillin, erythromycin, clindamycin, penicillin plus erythromycin,

134 ch of the colonizing isolates to penicillin, erythromycin, clindamycin, tetracycline, and other antim

135 timicrobial agents (penicillin, methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin,

136 ed an agar disk diffusion D-zone test and an erythromycin-clindamycin (ERY + CLI) single-well broth t

137 This study assessed an erythromycin-clindamycin (ERY-CC) broth test for inducib

138 ne fusidic acid resistance (fusC) (n = 181), erythromycin/clindamycin resistance (ermC) (n = 132) and

139 Erythromycin combines the antimicrobial effect and proki

140 Median gastric transit time was lower after erythromycin compared to domperidone (13 min versus 22 m

141 rption [3-OMG AUC360: 105.2 (28.9-157.0) for erythromycin compared with 91.8 (51.4-147.9) mmol/L . mi

142 h non-CF bronchiectasis, the 12-month use of erythromycin compared with placebo resulted in a modest

143 rescription of co-amoxiclav, with or without erythromycin, compared with those born to mothers who re

144 m each genus that were not selected at lower erythromycin concentrations.

145 ates were retained in vivo, with the H-TriA1-erythromycin conjugate proving a more effective treatmen

146 hesis of the clinically important antibiotic erythromycin D, the glycosyltransferase (GT) EryCIII, in

147 profloxacin, tetracycline, trimethoprim, and erythromycin, demonstrated pronounced differences in upt

148 a cryo-electron microscopy structure of the erythromycin-dependent ErmBL-SRC.

149 yo-electron microscopy (EM) structure of the erythromycin-dependent ErmCL-stalled ribosome at 3.9 A r

150 -substituted 2'-O,3'-N-carbonimidoyl bridged erythromycin-derived 14- and 15-membered macrolides.

151 fection dominated by Pseudomonas aeruginosa, erythromycin did not change microbiota composition signi

152 ents without P. aeruginosa airway infection, erythromycin did not significantly reduce exacerbations

153 Addition of erythromycin (Em) to a Bacillus subtilis strain carrying

154 A1 (H-TriA1) to rifampicin, vancomycin, and erythromycin enhanced their activity in vitro but not by

155 Bacteroides spp. that confers resistance to erythromycin [erm(F)] and tetracycline [tet(Q)].

156 stigated the ability of four combinations of erythromycin (ERY) and clindamycin (CC) (ERY and CC at 4

157 An erythromycin (ERY) detection method is proposed using th

158 (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezoli

159 ptococcus pneumoniae isolates are macrolide (erythromycin [ERY]) resistant (ERSP), most commonly due

160 ained not just in TraB proteins, but also in erythromycin esterase (Pfam ID: PF05139), DUF399 (domain

161 ind, placebo-controlled trial of twice-daily erythromycin ethylsuccinate (400 mg) in adult patients w

162 Twice-daily erythromycin ethylsuccinate (400 mg) or matching placebo

163 lptE14 mutation increased OM permeability to erythromycin, even when the wild-type lptE gene was pres

164 gnificant accumulation of 70S ribosomes upon erythromycin exposure.

165 train of S. erythraea with a higher titer of erythromycin expressed more BldD than a wild-type strain

166 The prescription of erythromycin for women in spontaneous preterm labour wit

167 Erythromycin given 30 min prior to endoscopic evaluation

168 ission, the groups were homogeneous, but the erythromycin group subjects achieved a shorter hospitali

169 ients, 42 in the placebo group and 44 in the erythromycin group.

170 clofenac, codeine, ampicillin, tetracycline, erythromycin-H2O, and gemfibrozil have significant pollu

171 Patients receiving erythromycin had nausea (20 [30%] vs 4 [6%]) and stomach

172 Co-amoxiclav (with or without erythromycin) had no effect on the proportion of childre

173 Although resistance to erythromycin has been recognised, beta-lactam resistance

174 However, erythromycin has been reported to increase the prevalenc

175 Erythromycin has strong gastric prokinetic properties.

176 e, norfloxacin, ofloxacin, tetracycline, and erythromycin) have been detected through chemical analys

177 We found resistance to erythromycin in 36% of the strains, and 33% were constit

178 ), double-blind, placebo-controlled trial of erythromycin in currently nonsmoking, adult patients wit

179 Trp ribosomes bind tylosin more readily than erythromycin in vivo.

180 Resistance to erythromycin increased markedly from 2.5% in 1991 to 15%

181 Erythromycin increased small intestinal glucose absorpti

182 Erythromycin increased the proportion of macrolide-resis

183 Acute administration of erythromycin increases small intestinal glucose absorpti

184 tructures illustrates the molecular basis of erythromycin-induced gene expression and provides a fram

185 The gastrokinetic drug erythromycin is commonly administered to critically ill

186 , the macrocyclic aglycone of the antibiotic erythromycin, is synthesized by a polyketide synthase (P

187 ts were administered in random order saline, erythromycin IV 150 mg, or morphine IV 0.05 mg/kg BW.

188 Erythromycin lacks colon prokinetic effect in children w

189 manometry to study the effect of intravenous erythromycin lactobionate at 1 mg/kg on colon motility i

190 Patients were randomized to intravenous erythromycin lactobionate, 3 mg/kg, or placebo 15 minute

191 lly important macrolide antibiotics, such as erythromycin, leading to the induction of the downstream

192 ple resistance to clindamycin, tetracycline, erythromycin, levofloxacin, or mupirocin was detected in

193 e as follows: amoxicillin < cephalosporins < erythromycin < tetracyclines < azithromycin < metronidaz

194 Rosamicin binds the erythromycin macrolide binding site approximately 60 ang

195 At 0.1 microg/ml erythromycin, macrolide-resistant mutants were induced i

196 Macrolide antibiotics such as erythromycin may improve clinical outcomes in non-cystic

197 re prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) compared with those prescribed a

198 clindamycin of >0.25 mug/ml, 44% had MICs to erythromycin of >0.25 mug/ml, and 16% had MICs to levofl

199 We quantified the effect of erythromycin on colon contraction by calculating the are

200 e was to evaluate the effects of intravenous erythromycin on small intestinal nutrient absorption and

201 concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly

202 voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; o

203 er, more children whose mothers had received erythromycin or co-amoxiclav developed cerebral palsy th

204 e other two are induced upon incubation with erythromycin or ethidium bromide.

205 an did those born to mothers who received no erythromycin or no co-amoxiclav, respectively (erythromy

206 vel of mercury-, tetracycline-, ampicillin-, erythromycin-, or chloramphenicol-resistant oral and uri

207 eceiving placebo and 6 (3-7) in 16 receiving erythromycin (P = .002).

208 halothin (P<0.0001), clindamycin (P = 0.04), erythromycin (P<0.0001), methicillin/oxacillin (P<0.0001

209 PKS genes from the pikromycin and erythromycin pathways were hybridized in Saccharomyces c

210 We examined the effects of erythromycin, penicillin, and virginiamycin at low conce

211 r protein docking site in the context of the erythromycin PKS resulted in decreased production of the

212 main, isolated from the fourth module of the erythromycin PKS, is presented at 1.85 A resolution.

213 The sensitivity of the erythromycin plus clindamycin combination of 1 mug/ml +

214 ons in single wells (1 mug/ml + 0.25 mug/ml [erythromycin plus clindamycin] and 1 mug/ml + 0.5 mug/ml

215 PKS resulted in decreased production of the erythromycin precursor 6-deoxyerythronolide B.

216 osphopantetheinylation of ACP domains of the erythromycin precursor polyketide synthase, 6-deoxyeryth

217 lyze if a single dose of orally administered erythromycin prior to capsule endoscopy results in a hig

218 ate is an attractive prospect as a pediatric erythromycin pro-drug.

219 compounds such as chloroquine, haloperidol, erythromycin, procainamide, and ofloxacin known to activ

220 lide B (the cyclized polyketide precursor to erythromycin) production in three common heterologous ho

221 rogen peroxide (H(2)O(2)) and an antibiotic (erythromycin) recognized by the MtrC-MtrD-MtrE efflux pu

222 Erythromycin reduced 24-hour sputum production (median d

223 Compared with placebo, erythromycin reduced the rate of pulmonary exacerbations

224 tions of azithromycin-, clarithromycin-, and erythromycin-related compounds reaching up to 25, 12, an

225 in [strA-strB], chloramphenicol [cat-1], and erythromycin resistance [mefA].

226 genes was insertionally inactivated with an erythromycin resistance cassette, and the mutants were a

227 cteroides conjugative transposon, carries an erythromycin resistance gene, ermB, and previously has b

228 Inducible expression of the erm erythromycin resistance genes relies on drug-dependent r

229 only when the antibiotic is present and the erythromycin resistance methyltransferase activity is cr

230 Here we show that erythromycin resistance methyltransferase expression red

231 ErmC is an erythromycin resistance methyltransferase found in many

232 interactions of the nascent peptide with the erythromycin resistance methyltransferase-modified ribos

233 nucleotide in the large ribosomal subunit by erythromycin resistance methyltransferases.

234 rimoxazole resistance occurred in 239 (66%), erythromycin resistance occurred in 132 (37%), and chlor

235 Beta-hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindam

236 The mutation conferring erythromycin resistance resulted from substitution of a

237 Erythromycin resistance was high at baseline and remaine

238 Erythromycin resistance was high for staphylococci (30.6

239 Erythromycin-resistance methyltransferases are SAM depen

240 ylococcus pseudintermedius isolates that are erythromycin resistant but clindamycin susceptible by in

241 ted species accounted for almost half of the erythromycin resistant enterococci isolated from the wet

242 A total of 8.8% of the isolates were erythromycin resistant, and 6.9% were clindamycin resist

243 ssembly and function, we isolated additional erythromycin-resistant E. coli mutants.

244 s recently been reported that ribosomes from erythromycin-resistant Escherichia coli strains, when is

245 Among 1,515 erythromycin-resistant isolates, 90.3% were of only thre

246 city of KsgA such that it acted similarly to erythromycin-resistant methyltransferases (Erms), rMtase

247 aries and selected the mutagenized cells for erythromycin-resistant mutants.

248 coccus pyogenes isolates from an outbreak of erythromycin-resistant pharyngitis in Pittsburgh, PA, we

249 ed activity against penicillin-resistant and erythromycin-resistant pneumococci.

250 leandomycin and diverse macrolides including erythromycin, respectively.

251 been linked to the presence of a functional erythromycin ribosomal methylase (erm) gene in most spec

252 lar chimeric PKSs harboring modules from the erythromycin, rifamycin, and rapamycin synthases.

253 pared with 53 of 66 patients (80%) receiving erythromycin (risk ratio, 1.26 [95% CI, 1.01-1.57]).

254 ing these strains the preferred option where erythromycin-sensitive 630 strains are required.

255 relied on the use of ermB-based mutagens in erythromycin-sensitive strains.

256 eous IS1 insertion in secA suppressed lptE14 erythromycin sensitivity by removing the C-terminal SecB

257 Erythromycin significantly reduced PDPEs both overall (m

258 Administering erythromycin significantly stimulated food intake compar

259 enrofloxacin, tetracycline, oxytetracycline, erythromycin, spinosad, cyclo-1,3,5,7-tetramethylene tet

260 pitalization and previous abdominal surgery, erythromycin still resulted in an increased completion r

261 Moreover, erythromycin stimulated food intake, suggesting a physio

262 Tetracycline, erythromycin, sulfonamide, and ciprofloxacin resistance

263 SMEG_3312 and MSMEG_6212 are associated with erythromycin susceptibility.

264 membrane destabilization resulting in better erythromycin synergies.

265 nal DH domains, EryDH4, from module 4 of the erythromycin synthase, and NanDH2 from module 2 of the n

266 sed more BldD than a wild-type strain during erythromycin synthesis.

267 n resistance rate estimates with penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethox

268 resistance of these isolates to ampicillin, erythromycin, tetracycline, streptomycin, trimethoprim-s

269 GET was significantly faster after erythromycin than either saline or morphine.

270 t, the cecal completion rate was higher with erythromycin than with domperidone, but there was no dif

271 e and week 48 was significantly greater with erythromycin than with placebo (median Bray-Curtis score

272 four major classes, including the macrolide erythromycin, the ketolide telithromycin, the lincosamid

273 s aureus is suppressed by chloramphenicol or erythromycin, the susceptibility of the bacteria to cath

274 %] of 249 vs 169 [29%] of 575, p=0.0016) and erythromycin (three [1%] of 249 vs 65 [11%] of 575, p=0.

275 letion of bldD in S. erythraea decreased the erythromycin titer in a liquid culture 7-fold and blocke

276 the ability of the motilin receptor agonist erythromycin to induce food intake.

277 es are warranted to confirm the potential of erythromycin to reduce the incidence of bronchoaspiratio

278 nctionality, the conversion of the ketone of erythromycin to the -N(Me)CH2- group in azithromycin lea

279 reases (E-4031, d-sotalol, thioridazine, and erythromycin) to little or no effect (haloperidol, moxif

280 aimed to assess whether long-term, low-dose erythromycin treatment changes the composition of respir

281 Long-term erythromycin treatment changes the composition of respir

282 The cecal completion rate was 86% after erythromycin versus 80% after domperidone (p = 0.03).

283 One patient receiving erythromycin vomited before induction of anesthesia.

284 The number needed to harm with erythromycin was 64 (95% CI 37-209) and with co-amoxicla

285 scription of a statin with clarithromycin or erythromycin was associated with a higher risk for hospi

286 In the sample evaluated erythromycin was associated with significant reductions

287 Resistance of VGS to penicillin and erythromycin was determined by the epsilometer test.

288 Erythromycin was particularly efficacious in the nontrau

289 ibiotics cefepime, ampicillin, amikacin, and erythromycin was proposed.

290 The AUC following erythromycin was significantly less compared to the fast

291 S. aureus the resistance to tetracycline and erythromycin were 55.2% (16/29) and 31.0% (9/29) respect

292 MICs for penicillin and erythromycin were correlated (P <0.05).

293 ional inhibitors rifampin, tetracycline, and erythromycin were found to be ineffective in preventing

294 Lomefloxacin and erythromycin were found to be the most potent compounds

295 eptible to chloramphenicol, clindamycin, and erythromycin were lower in 2003 and 2004 than in 2001 an

296 ominis, whereas penicillin, fusidic acid and erythromycin were the most frequent antibiotics the isol

297 adults, coprescription of clarithromycin or erythromycin with a statin that is metabolized by CYP3A4

298 dex) between baseline and week 48, comparing erythromycin with placebo.

299 functional impairment after prescription of erythromycin, with or without co-amoxiclav, compared wit

300 f children whose mothers had been prescribed erythromycin, with or without co-amoxiclav, had any func